Introduction
In adults, acute myeloid leukemia (AML) remains difficult to treat (1, 2) . The need for novel therapies is thus unquestioned. With increasing availability of specific small molecule inhibitors, considerable effort now focuses on targeting signaling pathways that are pivotal for leukemic cells as a means to improve therapeutic outcomes. Emerging evidence suggests that the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway (3, 4) could provide a rational drug target in AML. Constitutive activation of AKT, as indicated by phosphorylation at Thr308 and/or Ser473, is observed in 50-85% of patients with AML (5) (6) (7) (8) (9) (10) (11) (12) and has been correlated with adverse cytogenetics as well as inferior relapse-free and overall survival (11, 13, 14) . Activated AKT has been implicated in proliferation, myeloid transformation, cell survival, and chemoresistance of AML cells (6, 9, 10) ; in fact, induction of PI3K/AKT signaling may be one of the mechanisms by which bone marrow stroma cells confer protection from chemotherapy (15) . Conversely, inhibition of the PI3K/AKT signaling pathway restores apoptosis in AML cells in vitro (8) .
MK-2206 is an oral, highly specific allosteric inhibitor for all three isoforms of human AKT (16) . Preclinical studies confirmed efficient AKT dephosphorylation and demonstrated growth inhibition of various human solid tumor cell lines (17) (18) (19) (20) (21) (22) ; consequently, MK-2206 has entered clinical testing for patients with solid tumors (23) . On the other hand, the effects of MK-2206 on malignant hematopoietic cells are poorly explored so far except for recent studies, which indicated significant cytotoxic activity against diffuse large B-cell lymphoma and T-cell acute lymphoblastic leukemia (ALL) cells in vitro (24, 25) . In the current study, we have investigated the anti-tumor activity of MK-2206 against human AML cell lines and primary AML blasts. To begin testing this compound clinically, we then conducted a phase 1/2 trial in adults with poorprognosis AML to determine the drug's tolerability and obtain preliminary data on its efficacy of AKT inhibition. Weekly (34) rather than every-other-day (23) dosing of MK-2206 was explored following recommendations of the Cancer Therapy Evaluation Program at the National Cancer Institute (CTEP/NCI; see Treatment, Methods).
Methods

In Vitro Investigations
Materials
All reagents were purchased from commercial sources unless otherwise stated. MK- 
Analysis of cell viability and apoptosis
Cells were treated with various doses of MK-2206 for up to 72 hours. Cell viability and cell numbers were quantified by trypan blue dye exclusion assay using a Vicell. To determine the mechanism of cell death, cells were washed in phosphate-buffered saline, and resuspended in binding buffer containing Annexin V (Roche Diagnostics, Indianapolis, IN). Apoptotic cells were identified by positive Annexin V staining using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA).
Western blot analysis
OCI-AML3, MOLM13, or primary AML blasts were sonicated in lysis buffer (62.5 mM Tris (pH 8.0), 2% SDS, 10% glycerol, 100 µM AEBSF, 80nM Aprotinin, 5µM Bestatin, 1.5 µM E-64, 2 µM leupeptin, 1 µM Pepstatin, 500 µM sodium orthovanadate, 500 µM glycerol phosphate, 500
µM sodium pyrophosphate and 50 µM DTT), and protein (5 x 10 5 cell equivalents) was subjected to electrophoresis using 10-14% acrylamide/0.1% SDS gels. Proteins were transferred onto nitrocellulose, and membranes were probed with monoclonal antibodies against pAKT Thr308 and Ser473, phospho-S6, S6 (all from Cell Signaling Technology, Danvers, MA), and Tubulin (Sigma-Aldrich).
Clinical Trial
Study population
Research. clinical benefit from the trial drug could also remain on study beyond 3 months if no significant toxicities occurred.
Statistical considerations
The study's primary objective was to determine the proportion of patients achieving CR, CRp, or PR as best response within 3 cycles of therapy; secondary objectives included the estimation of disease-free survival of patients who achieved CR/CRp, and the establishment of the toxicity profile of MK-2206. A Simon two stage optimum design (35) was used to test the null hypothesis that the response rate (i.e. CR, CRp, or PR) at week 12 was ≤10% vs. the alternative that the response rate is ≥25% at an α level of .05 with 80% power. Patients who were removed from study therapy for reasons other than disease progression (e.g. noncompliance, fatal infections) before completion of 3 cycles of therapy were not included in the efficacy assessment, and additional patients were enrolled. With 3 or more responses in the first 18 patients, the trial would continue to accrue up to 43 patients; otherwise, the trial would stop early and the drug would be rejected for further study. With ≥8 responses among 43 patients enrolled, the drug would be considered effective. With this design, the probability of early termination was 73% if the true response rate was only 10%. With the concern of treatmentrelated toxicity, the non-hematologic toxicity (≥grade 3, with the exception of hyperglycemia) would also be continuously monitored during the study using established Bayesian-based methods (36) . The stopping rule was set such that the trial would be halted if, at any time during the study, there was a >90% chance that the toxicity rate exceeded 30%.
Biomarker analyses
Biomarkers studies were optional and only performed in samples from patients consenting to these studies. Peripheral blood samples were collected before and 24 hours after the first administration of MK-2206 during the initial treatment cycle, and bone marrow samples were collected at baseline and before the second treatment cycle. Mononuclear cells were separated by Ficoll gradients, and cell lysates were subjected to reverse phase protein array (RPPA) analysis following previously described and validated methods (26) (27) (28) . Slides were probed with 157 primary antibodies, including two recognizing pAKT (Thr308 and Ser473; both Cell Signaling Technology), a secondary antibody for signal amplification, and a stable dye for precipitation (29) . The slides were scanned, and images quantified using Microvigene Version loading bias by median-centering each marker and median-centering each sample (30, 37) . We used paired t-tests employing the Benjamini-Hochberg method for adjustment to control the false discovery rate (FDR) (38) to detect differential protein expression or phosphorylation of each protein in the following three subsets: (a) the target itself (pAKT Ser473 and Thr308); (b) selected proteins associated with AKT inhibition (4E-BP1-pS65, 4E-BP1-pT37-T46, Bim, Cyclin D1, FOXO3a pS318-S321, GSK3α-β pS21-S9, IRS1, Mcl1, mTOR pS2448, NF-kB-p65 pS536, p70S6K-pT389, PRAS40-pT246, PTEN, S6 pS235-S236, S6 pS240-S244, Survivin, and XIAP);
and (c) all 157 proteins. In subsets (a) and (b), we used one-sided tests because we could specify the expected directions of change a priori. Heat maps of selected markers and samples were plotted in Supplemental Figure 4 , where the data were median-centered for each marker.
Results
In Vitro Investigations of MK-2206 in Human AML Cells
In line with previous investigations in solid tumor cancer as well as ALL cells (18, Consistent with these cell line data, treatment with MK-2206 suppressed Ser473 AKT phosphorylation, pPRAS40, and p4EPBP1 (Thr37/46) in 3 primary AML samples tested ( Figure   1B ).
Having confirmed target inhibition with MK-2206, we then investigated the drug's effects on viability of various human AML cell lines. As shown in Table 1 1978 studies indicate that MK-2206 causes cell cycle arrest, growth inhibition, and -at higher drug concentrations -apoptosis in human AML cell lines and primary AML blasts.
Clinical Trial
Given the above findings, we conducted a phase 2 trial of MK-2206 in adults with poorprognosis AML to begin testing its clinical efficacy and tolerability in this disease. While initial clinical studies explored alternate dosing schedules (23) , preclinical data indicated that weekly dosing would be at least as efficacious. Thus, later clinical studies investigated MK-2206 given once weekly (34) . Building upon this experience, we administered MK-2006 at 200 mg weekly, the maximum tolerated dose established in patients with solid tumors (34) .
Over a period of 2 years, 19 adults with a median age of 70 years were enrolled in this study and received at least 1 dose of MK-2206 ( Table 2 ). The median number of cycles administered was 2, with 4 patients completing ≥3 cycles. Eighteen patients were eligible for efficacy and toxicity assessments. One patient was not included in these analyses because of study removal after 1 cycle due to non-compliance; at that time, however, this patient had stable disease and no evidence of drug-associated toxicities. Among the 18 eligible patients, only 1 CRp was observed (5.6%; exact 95% confidence interval: 0-17%). This patient was a 77-year old male with normal-karyotype secondary AML without FLT3, KIT or RAS mutations that arose from antecedent chronic myelomonocytic leukemia. He initially achieved CR with clofarabine/low-dose cytarabine but then relapsed and failed a first salvage therapy with twicedaily fludarabine and cytarabine. He achieved a CRp after the first cycle of MK-2206 with a decrease in bone marrow blasts from 13% to <5%. Subsequently, his leukemia burden fluctuated over the next several months of therapy between 4% and 15%, and he was removed from study after completion of 11 treatment cycles. In contrast, the 17 non-responders were removed from study for disease progression after 1 cycle (n=7), 2 cycles (n=8), 3 cycles (n=1), or 4 cycles (n=1), respectively.
In general, MK-2206 monotherapy was reasonably well tolerated. However, as the most common grade 3/4 adverse event related to study drug, a pruritic rash occurred in 6/18 evaluable patients (33.3%); this side effect led to dose-reduction in 3 patients (135 mg/weekly) and discontinuation of drug in 1. Besides milder (grade 1/2) rashes in another 4 patients (Table 3) .
Ultimately, the study was terminated early after inclusion of 18 eligible patients because of insufficient drug efficacy, as per predefined stopping rules. Finally, we conducted proteomic analyses to investigate the degree of target inhibition with MK-2206 utilizing RPPA in paired peripheral blood specimens -obtained prior to and 24 hours after the first dose of MK-2206 -in 8 patients, as well as in paired bone marrow specimens -obtained prior to and 28 days after the first dose of MK-2206 -in 5 patients, respectively. Two patients (#1 and #17, the latter with extramedullary disease only) who had low pAKT levels in the baseline samples (less than -4.0 on log 2 scale) were excluded from this analysis and, unfortunately, the sole responding patient did not consent to these optional biomarker studies. Considering AKT alone, the decrease in Ser473 AKT was significant (P=0.018). However, the larger sets (i.e. testing direct AKT targets or the entire 157 proteins)
showed no significant changes after adjusting for multiple testing. Of note, a decrease in Ser473 AKT (median 28%; range, 12-45%) was seen in 5/7 peripheral blood and 3/4 bone marrow specimens, while a reduction in Thr308 AKT phosphorylation was found in 5/7 peripheral blood as well as 3/4 bone marrow samples, respectively ( Figure 3A and 3B) . In turn, changes in AKT targets were less evident (downregulation of pFOX3A in 3/7, pPRAS40 in 2/7, pS6K in 4/7 and p4EBP1 in 2/7 PB samples), possibly due to incomplete AKT inhibition. In samples with sufficient amounts of protein available, confirmatory immunoblotting was performed, which showed findings consistent with RPPA. Specifically, ≥50% downregulation of pAKT-473 was seen in peripheral blood samples from subjects #2, 3, 7 and in bone marrow sample #6, with lesser decreases in the mTOR targets, pS6 and p4EBP1 ( Figure 4A and 4B), with changes in pAKT being highly concordant between the two techniques (P=0.01, Supplemental Figure 3 ).
With regard to downstream targets or other proteins including phosphorylated MAPK, no significant changes were found after adjustment for multiple testing by RPPA ( Figure 3A 
Discussion
The in vitro data presented in this study showing that AKT inhibition impairs the survival of AML cells provide further rationale for selecting this signaling pathway as pharmacologic target in AML. However, our findings also indicate that the oral AKT inhibitor, MK-2206, has insufficient activity as a single agent in patients with relapsed/refractory AML at the chosen dose. While initial studies with MK-2206 were conducted using every-other-day drug dosing, a weekly dosing schedule was explored because of the drug's long half-life (60-80h) and an attempt to ameliorate feedback activation of alternative signaling pathways in response to continuous AKT inhibition. Despite the fact that MK-2206 was reasonably well tolerated in our study cohort, the frequent occurrence of grade 3/4 rash suggests that dose-escalation at the weekly schedule may not be feasible. Skin toxicity was also a prominent toxicity in solid tumor patients who received MK-2206 at doses higher than 60 mg every other day (23), a finding that disabled escalation of drug dosing in those patients.
In our study population, an objective response was documented in only one patient, 
